Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going

Luis Gabriel Parra-Lara\textsuperscript{a,}\textsuperscript{*}, Juan José Martínez-Arboleda\textsuperscript{a}, Fernando Rosso\textsuperscript{a,}\textsuperscript{b,}\textsuperscript{c}

\textsuperscript{a}Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122–135, Cali 760031, Colombia
\textsuperscript{b}Servicio de Infectología, Departamento de Medicina Interna, Fundación Valle del Lili, Cali 760032, Colombia
\textsuperscript{c}Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cali 760032, Colombia

Azithromycin is a macrolide antibiotic with a 15-membered lactone ring. It has excellent tissue penetration and its antimicrobial activity is due to inhibition of the 50S ribosomal subunit that prevents the synthesis of proteins in a wide range of Gram-positive and Gram-negative bacteria. Anti-inflammatory effects of azithromycin include modulating the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and IL-1\textbeta and acceleration of phagocytosis by macrophages, classifying azithromycin as a senolytic drug that selectively attacks and kills senescent cells with an efficiency of almost 97\% [1–3].

This macrolide has also been shown to have antiviral properties for respiratory viruses, such as rhinoviruses, by decreasing the synthesis of intercellular adherence molecules such as ICAM-1 that are used by the virus for adhesion [4]. All of the abovementioned has generated new hypotheses and opened a new prospect for older adult patients with high mortality from coronavirus disease 2019 (COVID–19), which should be evaluated in future research.

In an open-label clinical trial conducted in France, it was recently shown that azithromycin, in combination with hydroxychloroquine (HCQ), inhibits replication of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [5]. However, the effects of azithromycin alone were not evaluated. The study included 36 patients (20 HCQ-treated and 16 control patients) who were positive for SARS-CoV-2 by PCR. The researchers demonstrated that HCQ (14/20; 70.0\%) was superior to standard management (2/16; 12.5\%) for the eradication of SARS-CoV-2 (P = 0.001). Among the HCQ-treated patients, azithromycin was prescribed to six patients with the initial goal of preventing bacterial superinfection and it was found that in this subgroup viral eradication was much higher (6/6; 100\%) on Day 6 of treatment compared with those who received HCQ as monotherapy (8/14; 57.1\%). The azithromycin dose was 500 mg on Day 1 followed by 250 mg/day for the next 4 days. However, these data must be interpreted with caution. The group of patients who received HCQ as monotherapy had significantly higher viral loads than those who received the combined therapy with azithromycin, so the true adjuvant efficacy of this drug may be overestimated in the virus eradication rates [5].

Other authors suggest that with the findings of this study, together with previous research on the effect of macrolides on rhinoviruses, respiratory syncytial virus, influenza virus and Zika virus, among others, make drugs such as erythromycin conspicuous for future research in COVID-19 [6]. However, the mechanism by which the combination of a macrolide with HCQ prevents production of the SARS-CoV-2 virus remains unknown, and to date no in vitro studies have been reported with results in this regard.

\* Corresponding author.
\textit{E-mail addresses:} luisgabrielparralara@hotmail.com, luis.parra5@correo.icesi.edu.co (L.G. Parra-Lara).

http://dx.doi.org/10.1016/j.jgar.2020.06.016
2213-7165/\textcopyright 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
| NCT ID         | Recruiting status | Location | Design/phase | Country | Population | Intervention group(s) | Comparison group(s) | Primary outcome | Safety outcome |
|---------------|-------------------|----------|--------------|---------|------------|--------------------|-------------------|----------------|----------------|
| NCT04329832  | Recruiting        | USA      | Open-label, RCT/phase 2 | Confirmed or suspected COVID-19, age ≥ 18 years (n = 300) | HCQ 400 mg PO b.i.d. for 1 day, then 200 mg PO b.i.d. for 4 days | AZM 500 mg PO on Day 1, then 250 mg PO daily on Days 2–5 | COVID-19 ordinal outcomes scale at 14 days | No data          |
| NCT04334382  | Recruiting        | USA      | Open-label, RCT/phase 3 | COVID-19-confirmed adults, age ≥44 years (n = 1550) | HCQ 400 mg PO b.i.d. for 1 day, then 200 mg PO b.i.d. for 4 days | AZM 500 mg PO on Day 1, then 250 mg PO daily on Days 2–5 | Hospitalisation within 14 days of enrolment | No data          |
| NCT04332107  | Recruiting        | USA      | Quadruple blinded⁵, RCT/phase 3 | Positive SARS-CoV-2 test, age ≥18 years (n = 2271) | Single 1 g dose of AZM PO | Placebo | – | Incidence of gastrointestinal adverse events; cardiac toxicity | No data          |
| NCT04339426  | Recruiting        | USA      | Open-label, non-RCT⁷/phase 2 | COVID-19 confirmed, age ≥18 years (n = 25) | Ato伐quaone 750 mg PO b.i.d. for up to 10 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for up to 10 days | – | Virolology cure rate; COVID-19 serology testing | No data          |
| NCT043329572 | Recruiting        | Brazil   | Open-label, non-RCT⁷/early phase 1 | SARS-CoV-2 infection confirmed by RT-PCR, age ≥18 years (n = 400) | HCQ 400 mg PO b.i.d. for 1 day, then 400 mg/day PO for 4 days/AZM 500 mg PO daily for 5 days | – | Evolution of acute respiratory syndrome, oxygen saturation, haemodynamic stability | No data          |
| NCT04339816  | Recruiting        | Czech Republic | Triple blinded⁷, RCT/phase 3 | Proven or suspected COVID-19 infection, age ≥18 years (n = 240) | AZM 500 mg PO or via NG tube for 1 day, then AZM 250 mg PO or via NG tube daily for 4 days (with first daily dose of HCQ)/HCQ 400 mg PO or via NG tube b.i.d., then 200 mg PO b.i.d. or via NG tube for 4 days | Active comparator: HCQ 400 mg PO or via NG tube b.i.d., then 200 mg PO b.i.d. or via NG tube (with the first daily dose of HCQ). Placebo comparator: placebo PO or via NG tube b.i.d., and one extra dose of placebo once in 24 h per 5 days Sarilumab 400 mg i.v. in 1 h for 1 day | Proportion of alive patients free of mechanical ventilation | No data          |
| NCT04341870  | Suspected         | France   | Open-label, RCT/phase 2 and phase 3 | COVID-19, age 18–80 years (n = 60) | Sarilumab 400 mg i.v. in 1 h for 1 day/AZM 500 mg PO for 1 day, then 250 mg daily for 4 days/HCQ 200 mg PO t.i.d. for 10 days | Group B: HCQ 200 mg PO t.i.d. for 10 days | Need for ventilation | No data          |
| NCT04336332  | Recruiting        | USA      | Open-label, RCT/phase 2 | SARS-CoV-2 infection, age 18–89 years (n = 160) | HCQ 200 mg PO t.i.d. for 10 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days | Group C: supportive care for 6 days; if patient still has COVID-19 symptoms, they will receive HCQ 200 mg PO t.i.d. for 10 days HCQ 400 mg PO b.i.d. for 1 day, then 200 mg PO b.i.d. for 6 days/AZM 500 mg PO daily for 3 days | Changes in patient’s viral load | No data          |
| NCT04332094  | Recruiting        | Spain    | Open-label, RCT/phase 2 | SARS-CoV-2 infection confirmed, age ≥18 years (n = 276) | Tocilizumab 162 mg s.c. × 2 doses, then tocilizumab 162 mg s.c. × 2 doses at 12 h (Day 1)/HCQ 400 mg PO b.i.d. for 1 day, then 200 mg PO b.i.d. for 6 days/AZM 500 mg PO daily for 3 days | Group A: SOC/HCQ 800 mg PO or via feeding tube for 1 day, then 600 mg daily for 4 days. Group B: SOC/AZM 500 mg PO or via feeding tube for 1 day, then 250 mg PO daily for 4 days. Group C: SOC/HCQ 800 mg PO or via feeding tube, then 600 mg daily for 4 days/AZM 500 mg PO or via feeding tube for 1 day, then 250 mg PO daily for 4 days | In-hospital mortality; need for mechanical ventilation in the ICU | No data          |
| NCT04335552  | Recruiting        | USA      | Open-label, RCT/phase 2 | Symptoms suggestive of COVID-19 infection or develop symptoms of COVID-19 during hospitalisation, age ≥18 years (n = 500) | – | SOC | – | – | – |

① HCQ = Hydroxychloroquine ② NCT = National Clinical Trials ③ AZM = Azithromycin ④ COVID-19 = Coronavirus Disease 2019 ⑤ SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus ⑥ NACO = National Anti-Microbial Resistance Journal ⑦ RCT = Randomized Controlled Trial ⑧ RCT/phase 2 = Randomized Controlled Trial/Phase 2 ⑨ RCT/phase 3 = Randomized Controlled Trial/Phase 3 ⑩ RCT/early phase 1 = Randomized Controlled Trial/Early Phase 1

Table 1
Summary of clinical trials for azithromycin (AZM) in coronavirus disease 2019 (COVID-19) (n = 21).

L.C. Perso-Lara et al., Journal of Global Anti-Microbial Resistance, 22 (2020) 680–684

681
| NCT ID        | Recruiting status | Location | Design/phase       | Country       | Population                                                                 | Intervention group(s)                                                                 | Comparison group(s)                                                                 | Primary outcome                                                                 | Safety outcome |
|--------------|-------------------|----------|-------------------|---------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------|----------------|
| NCT04341207  | Recruiting       | SC       | Open-label, non-RCT/phase 2 | France        | All types of locally advanced and metastatic malignancy, age ≥18 years (n = 1000) | Cohort 1: HCQ 200 mg PO t.i.d. for 10 days/AZM 500 mg PO for 1 day, then 250 mg daily for 4 days. | Cohort 2: no intervention, advanced cancer patients with SARS-CoV-2-negative test and COVID-19 symptoms | Prevalence and 3-month incidence of SARS-CoV-2 in cancer patients; COVID-19-specific mortality rate in cancer patients treated with HCQ and AZM | No data         |
| NCT04328272  | Not yet recruiting | SC       | Single masking, RCT/phase 3 | Pakistan      | COVID-19 confirmed by RT-PCR, age 18–50 years (n = 75)                      | HCQ 800 mg PO first dose, then after 6 h 600 mg PO (Day 1), followed 200 mg PO b.i.d. for 6 days | Active comparator: AZM 500 mg PO for 1 day, then 250 mg PO daily for 6 days. Placebo comparator: placebo (sugar tablet) b.i.d. for 7 days | No data         | No data         |
| NCT04338698  | Not yet recruiting | SC       | Double blinded, RCT/phase 3 | Pakistan      | Confirmed SARS-CoV-2, age ≥18 years (n = 500)                             | HCQ 200 mg PO t.i.d. for 5 days Comparator 1: AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 2: oseltamivir 75 mg PO b.i.d. for 5 days. Comparator 3: HCQ 200 mg PO t.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 4: HCQ 200 mg PO t.i.d. for 5 days/ oseltamivir 75 mg PO b.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 5: HCQ 200 mg PO t.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 6: HCQ 200 mg PO t.i.d. for 5 days/ oseltamivir 75 mg PO b.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. | Laboratory results; clinical outcomes | No data         |
| NCT04321278  | Completed        | MC       | Open-label, RCT/phase 3  | Brazil        | Probable or confirmed infection by SARS-CoV2, age ≥18 years (n = 440)     | HCQ 400 mg PO b.i.d./AZM 500 mg PO daily for 10 days                                    | Evaluation of clinical status                                                                 | QT prolongation; gastrointestinal intolerance; laboratory abnormalities; adverse events | No data         |
| NCT04322396  | Recruiting       | SC       | Quadruple blinded, RCT/phase 2 | Denmark       | Positive COVID-19 test/diagnosis during hospitalisation, age >18 years (n = 226) | AZM and HCQ in 15 days                                                                  | Placebo in 15 days                                                                                       | Number of days alive and discharged from hospital within 14 days Evaluation of clinical status | No data         |
| NCT04322123  | Active, not recruiting | MC       | Open-label, RCT/phase 3 | Brazil        | Suspected or confirmed COVID-19 admitted to inpatient units and ICUs, age ≥18 years (n = 630) | HCQ 400 mg PO b.i.d. for 7 days Comparator 1: AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 2: oseltamivir 75 mg PO b.i.d. for 5 days. Comparator 3: HCQ 200 mg PO t.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 4: HCQ 200 mg PO t.i.d. for 5 days/ oseltamivir 75 mg PO b.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 5: HCQ 200 mg PO t.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 6: HCQ 200 mg PO t.i.d. for 5 days/ oseltamivir 75 mg PO b.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. | Standard treatment protocol for COVID-19                                                                 | Safety outcome on QTc                                                                                       | No data         |
| NCT04324463  | Recruiting       | SC       | Open-label, RCT/phase 3  | Canada        | COVID-19 confirmed, age ≥18 years (n = 1500)                              | CQ 500 mg PO b.i.d. for 7 days Comparator 1: AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 2: oseltamivir 75 mg PO b.i.d. for 5 days. Comparator 3: HCQ 200 mg PO t.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 4: HCQ 200 mg PO t.i.d. for 5 days/ oseltamivir 75 mg PO b.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 5: HCQ 200 mg PO t.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Comparator 6: HCQ 200 mg PO t.i.d. for 5 days/ oseltamivir 75 mg PO b.i.d. for 5 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. | SOC Outpatients: hospital admission or death. Inpatients: invasive mechanical ventilation or mortality | No data         |
| NCT04334512 | Recruiting | SC  | Open-label single-group clinical trial/phase 2 | USA | Diagnosis of COVID-19 by RT-PCR, age 18–55 years ($n = 60$) | Quintuple therapy for 24 weeks (HCQ, AZM, vitamin C, vitamin D, zinc) | Successful treatment as determined by negative RT-PCR test and resolution of symptoms; safety of quintuple therapy |
| NCT04341727 | Suspended | MC  | Open-label, RCT/phase 3 | USA | Positive SARS-CoV-2 test, age ≥18 years ($n = 500$) | Arm 1: HCQ 400 mg PO b.i.d. for 1 day, then 200 mg PO b.i.d. for 4 days. Arm 2: HCQ 400 mg PO b.i.d. for 1 day, then 200 mg PO b.i.d. for 4 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days. Arm 3: CQ 1000 mg PO once, followed in 12 h by 500 mg, then 500 mg PO b.i.d. for 4 days. Arm 4: CQ 1000 mg PO once, followed in 12 h by 500 mg, then 500 mg PO b.i.d. for 4 days/AZM 500 mg PO for 1 day, then 250 mg PO daily for 4 days | Hours to recovery |
| NCT04332835 | Not yet recruiting | SC  | Open-label, RCT/phase 2 and phase 3 | Colombia | Diagnosis of COVID-19 by RT-PCR, age 18–60 years ($n = 80$) | Day 1: CP 250 mL. Day 2: CP 250 mL/HQ 400 mg PO b.i.d. for 10 days/ AZM 500 mg daily for 10 days | HCQ 400 mg PO b.i.d. for 10 days/AZM 500 mg daily for 10 days | Change in viral load; change in IgM COVID-19 titres; change in IgG and IgG COVID-19 titres |
| NCT04323345 | Recruiting | SC  | Single masked, RCT/phase 3 | Egypt | COVID-19, age 5–75 years ($n = 1000$) | Natural honey supplement 1 g/kg/day PO or NG tube divided into 2–3 doses for 14 days/SOC | SOC | Rate of recovery from positive to negative swaps; resolution of lung inflammation on CT or radiography |

b.i.d., twice a day; CP, convalescent plasma; CQ, chloroquine; CT, computed tomography; ECG, electrocardiogram; HCQ, hydroxychloroquine; ICU, intensive care unit; Ig, immunoglobulin; i.v., intravenous; MC, multicentre; NG, nasogastric; PO, orally; RCT, randomised clinical trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; s.c., subcutaneous; SC, single centre; SOC, standard of care; t.i.d., three times a day; VO, ? .

* Participant, care provider, investigator, outcomes assessor.

* Single group assignment.

* Participant, care provider, outcomes assessor.

* Investigator, outcomes assessor.

* Investigator.
Another study by Molina et al. also evaluated the efficacy of the combination of azithromycin and HCQ using the same doses [7]. Eleven patients positive for SARS-CoV-2 by PCR were included in this study. All were given HCQ plus azithromycin combined therapy and 10 underwent repeat PCR on the sixth day after starting treatment; 8/10 patients (80%) had no virological clearance and continued to test positive for SARS-CoV-2. These data are inconsistent with those reported by Gautret et al. [5] and raise doubts about the true antiviral efficacy of this combination. On the other hand, a case series carried out in a single centre in Wuhan, China, that included 138 patients, of which 36 (26.1%) required intensive care unit (ICU) management and 6 (4.3%) died, it was found that the majority of patients received oseltamivir (124; 89.9%) and only 25 (18.1%) received azithromycin [8].

A wide variety of azithromycin-related adverse effects involving all the systems of the human body have been described, which vary in severity and frequency. Among the most frequent are gastrointestinal disorders such as nausea, vomiting and diarrhoea, which are seen in up to 10% of cases. Albeit at low frequency, severe side effects can predispose patients to life-threatening scenarios and arrhythmias such as QT prolongation. The mechanism by which the QT interval is prolonged is by blocking the external flow of potassium ions from the ventricular myocytes to the extracellular fluid that stimulates ventricular repolarisation.

HCQ has also been shown to have cardiac effects including QT prolongation, therefore concomitant use of HCQ with azithromycin could potentiate these effects, an aspect that should be considered when prescribing this combination. The potential of HCQ to prolong ventricular repolarisation is not as well documented, but cases of QT prolongation have been reported during chronic treatment [9].

Only a few clinical studies have analysed the cardiovascular effects of these drugs in the past [10] and they concluded that indeed they have an effect on the QT interval and, when combined, this effect is increased. Recent studies in COVID-19 patients show this additive effect; for example, a study conducted in Boston (USA) showed that in a cohort of 90 patients given HCQ, those receiving concomitant azithromycin (53 patients) had a greater median (interquartile range) change in QT interval [23 (10 to 40) ms] compared with those receiving HCQ alone [5.5 (15.5 to 34.25) ms] (P = 0.03) [11].

Despite the mentioned cardiac effects, their appearance may be reduced in a controlled clinical setting. Giudicessi et al. proposed that together with other parameters such as electrolytes and co-morbidities, depending on the length of the QT interval, it can be determined whether or not the patient is a candidate for use of these drugs [12]. Patients with a QT interval of ≥460 ms are candidates for pharmacological therapy categorised in the ‘green light’ category, whilst those with a QT interval of >460 ms (categorised as ‘yellow’ or ‘red light’ status) are at greater risk of complications such as torsade de points, therefore the cost–benefit ratio of the management should be very well evaluated. Their data are encouraging since they estimate that the vast majority of patients (90%) will be categorised as ‘green’, making them candidates [12].

Finally, regulatory entities such as the European Medicines Agency (EMA), although not fully recommending the use of the aforementioned combination of drugs owing to their adverse effects, support their use under strict medical supervision and always considering the possibility of the aforementioned adverse effects. Therefore, in the context of COVID-19, these drugs should only be used as part of clinical trials or parallel to national security protocols [13]. Future research should consider, in addition to their combined efficacy, their combined safety profile.

There are currently 21 clinical trials registered on ClinicalTrials.gov for azithromycin related to COVID-19 (see Table 1). Thirteen studies have already started the patient recruitment process, twelve will be carried out in a single centre, and eight will be carried out in the USA. Ongoing trials vary in design, comparison group, drug dose and duration, target population and primary endpoints. Only five studies include safety outcomes. The foregoing is an international call and effort to seek therapeutic strategies to control the COVID-19 pandemic that currently affects 180 countries on all continents. Based on these results, therapeutic guidelines can be established for patients with COVID-19 based on scientific evidence and will clarify the effectiveness of azithromycin against SARS–CoV-2.

**References**

1. Sargiacomo C, Setgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of coronavirus infection? Aging (Albany NY) 2020;12:6511–7. doi:http://dx.doi.org/10.18632/ageing.103001.

2. Kagalwala K, Makri OE, Georgakopoulou CD, Panayiastalakopoulou GD. An eye for azithromycin: review of the literature. Ther Adv Ophthalmol 2018;10:251841878362, doi:http://dx.doi.org/10.1177/2518418783622.

3. Banjanc A, Munic V, Nujic K, Vrančić M, Bemalanc D, Crnkovic S, et al. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. Pharmacol Res 2012;66:357–62, doi:http://dx.doi.org/10.1016/j.phrs.2012.06.011.

4. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010;36:546–54, doi:http://dx.doi.org/10.1183/09031936.00095809.

5. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 March] 105949, doi:http://dx.doi.org/10.1016/j.ijantimicag.2020.105949 [Epub ahead of print].

6. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide treatment for COVID-19: will this be the way forward? Biosci Trends 2020;14:159–60, doi:http://dx.doi.org/10.5582/bst.2020.03058.

7. Molina JM, Delauregger C, Le Goiff, M-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 Infection. Med Mal Infect 2020;50:384, doi:http://dx.doi.org/10.1016/j.medmal.2020.03.006.

8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9, doi:http://dx.doi.org/10.1001/jama.2020.3585.

9. Chen C-Y, Wang F-L, Lin C-C. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 2006;44:173–5, doi:http://dx.doi.org/10.1080/155635050514558.

10. Hancox JC, Hassan M, Vieweg WVR, Crouse TJ, Baranchuk A. Azithromycin, cardiovascular risks, QT interval prolongation, torsade de points, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infect Dis 2013;1:155–65, doi:http://dx.doi.org/10.1177/2049936113501816.

11. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Ziemerbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020(May) e201834, doi:http://dx.doi.org/10.1001/jamacardio.2020.1834 [Epub ahead of print].

12. Guidicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc 2020;95:1213–21, doi:http://dx.doi.org/10.1016/j.mayocp.2020.03.024.

13. European Medicines Agency (EMA). COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine. EMA: Amsterdam, the Netherlands; 2020. https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine.